Progyny (PGNY - Free Report) closed the last trading session at $27.15, gaining 2.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34 indicates a 25.2% upside potential.
The average comprises 12 short-term price targets ranging from a low of $30.00 to a high of $40.00, with a standard deviation of $3.19. While the lowest estimate indicates an increase of 10.5% from the current price level, the most optimistic estimate points to a 47.3% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for PGNY, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You May Not Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in PGNYAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current year, one estimate has moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 5%.
Moreover, PGNY currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much PGNY could gain, the direction of price movement it implies does appear to be a good guide.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.
Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
Canada Pension Plan Investment Board acquired a new stake in Progyny, Inc. (NASDAQ:PGNY – Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 23,600 shares of the company’s stock, valued at approximately $680,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in PGNY. BlackRock Inc. acquired a new position in shares of Progyny in the 2nd quarter worth approximately $334,426,000. Wellington Management Group LLP grew its position in Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares during the period. Fort Washington Investment Advisors Inc. OH raised its stake in Progyny by 46.9% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after acquiring an additional 859,289 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in Progyny during the fourth quarter worth $19,917,000. Finally, William Blair Investment Management LLC bought a new position in shares of Progyny during the second quarter valued at $16,807,000. 94.93% of the stock is owned by institutional investors.
Progyny Stock Performance NASDAQ PGNY opened at $25.66 on Wednesday. The business has a 50 day simple moving average of $29.04 and a 200 day simple moving average of $23.70. Progyny, Inc. has a 52-week low of $16.10 and a 52-week high of $33.06. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of 27.89, a PEG ratio of 1.77 and a beta of 1.01.
Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. The business had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, analysts predict that Progyny, Inc. will post 1.25 EPS for the current year. Progyny declared that its Board of Directors has authorized a stock buyback plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 10.3% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.
Analyst Ratings Changes A number of research firms recently issued reports on PGNY. Bank of America lifted their price target on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Wells Fargo & Company assumed coverage on shares of Progyny in a research report on Thursday, August 20th. They issued an “overweight” rating and a $37.00 price objective for the company. KeyCorp boosted their target price on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Barclays reduced their target price on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 12th. Finally, Wall Street Zen cut shares of Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.91.
Read Our Latest Analysis on Progyny
Insider Buying and Selling at Progyny In other Progyny news, CFO Mark S. Livingston sold 2,517 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the sale, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.90% of the stock is owned by company insiders.
Progyny Profile (Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Read More Five stocks we like better than Progyny Dutch Bros Sell-Off Creates a Growth Opportunity NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat Is Abercrombie & Fitch’s Hot Streak Just Getting Started? Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
Hsbc Holdings PLC acquired a new stake in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 26,394 shares of the company’s stock, valued at approximately $760,000.
Several other large investors have also recently bought and sold shares of PGNY. Royal Bank of Canada raised its holdings in Progyny by 384.8% in the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after purchasing an additional 10,340 shares during the period. Amundi lifted its holdings in Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after acquiring an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after acquiring an additional 14,297 shares in the last quarter. Invesco Ltd. grew its stake in Progyny by 37.4% in the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after acquiring an additional 103,253 shares during the period. Finally, Walleye Capital LLC increased its holdings in shares of Progyny by 6.9% in the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after acquiring an additional 780 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.
Wall Street Analyst Weigh In Several equities analysts have recently weighed in on PGNY shares. Barclays cut their price objective on Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 12th. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Canaccord Genuity Group set a $35.00 price objective on shares of Progyny in a report on Friday, August 7th. KeyCorp upped their target price on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Weiss Ratings downgraded Progyny from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and an average target price of $33.91.
View Our Latest Research Report on Progyny Insider Activity In other news, CFO Mark S. Livingston sold 2,517 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the sale, the chief financial officer owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. This represents a 3.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.90% of the stock is currently owned by corporate insiders.
Progyny Trading Up 0.3% Shares of PGNY stock opened at $25.66 on Wednesday. The firm’s fifty day moving average price is $29.04 and its two-hundred day moving average price is $23.70. Progyny, Inc. has a 1 year low of $16.10 and a 1 year high of $33.06. The firm has a market capitalization of $1.97 billion, a P/E ratio of 27.89, a PEG ratio of 1.77 and a beta of 1.01.
Progyny (NASDAQ:PGNY – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. The company had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.Progyny’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities research analysts forecast that Progyny, Inc. will post 1.25 EPS for the current fiscal year.
Progyny declared that its Board of Directors has approved a share repurchase plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy up to 10.3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.
Progyny Profile (Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Featured Stories Five stocks we like better than Progyny Dutch Bros Sell-Off Creates a Growth Opportunity NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat Is Abercrombie & Fitch’s Hot Streak Just Getting Started? Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
AWM Investment Company Inc. bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 220,000 shares of the company’s stock, valued at approximately $6,343,000. AWM Investment Company Inc. owned about 0.29% of Progyny at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Progyny in the second quarter worth approximately $334,426,000. Wellington Management Group LLP raised its holdings in Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its holdings in Progyny by 46.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after buying an additional 859,289 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in Progyny during the 4th quarter valued at $19,917,000. Finally, William Blair Investment Management LLC purchased a new stake in Progyny during the 2nd quarter valued at $16,807,000. 94.93% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades Several equities analysts have recently commented on the stock. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Canaccord Genuity Group set a $35.00 price target on Progyny in a report on Friday, August 7th. Leerink Partners set a $38.00 price target on Progyny in a report on Wednesday, July 22nd. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Finally, Wells Fargo & Company assumed coverage on Progyny in a report on Thursday, August 20th. They issued an “overweight” rating and a $37.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.91.
Read Our Latest Research Report on PGNY Progyny Stock Up 1.5% Progyny stock opened at $25.82 on Wednesday. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06. The company has a market capitalization of $1.98 billion, a P/E ratio of 28.07, a PEG ratio of 1.85 and a beta of 1.01. The stock’s 50 day moving average is $29.08 and its 200 day moving average is $23.55.
Progyny (NASDAQ:PGNY – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. The business had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities analysts expect that Progyny, Inc. will post 1.19 EPS for the current year.
Progyny declared that its board has approved a stock repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.
Insider Transactions at Progyny In other news, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider owned 59,117 shares of the company’s stock, valued at $1,512,212.86. The trade was a 2.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark S. Livingston sold 2,517 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the sale, the chief financial officer owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. The trade was a 3.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,563 shares of company stock valued at $351,968. 9.90% of the stock is owned by company insiders.
Progyny Profile (Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Further Reading Five stocks we like better than Progyny Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen analysts that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating
Liquidity measures a company’s capability to meet short-term debt obligations. Investors seeking strong portfolio returns should benefit from adding stocks with sound liquidity, which encourages business growth. Stocks with high liquidity have long been in demand because of their potential to deliver strong returns.
Investors may want to consider adding four top-ranked stocks — monday.com Ltd. (MNDY - Free Report) , Match Group, Inc. (MTCH - Free Report) , Progyny, Inc. (PGNY - Free Report) and Workiva (WK - Free Report) — to their portfolios to boost returns.
However, it is important to exercise caution. While high liquidity can indicate that a company is efficiently managing its short-term obligations, it may also suggest underutilization of resources. In some cases, companies with excess liquidity may not be deploying their assets effectively, which could limit growth potential.
Hence, one may consider a company’s efficiency level in addition to its liquidity while identifying prospective winners. A balanced assessment of both liquidity and efficiency can help identify truly promising investment opportunities.
Current Ratio: It measures current assets relative to current liabilities. The ratio gauges a company’s potential to meet short and long-term debt obligations. A current ratio — the working capital ratio — below 1 indicates that the company has more liabilities than assets. A high current ratio does not always suggest that the company is in good financial shape. It may also indicate that the firm failed to utilize its assets significantly. Hence, a range of 1-3 is considered ideal.
Quick Ratio: Unlike the current ratio, the quick ratio — the “acid-test ratio” or “quick assets ratio” — indicates a company’s ability to pay short-term obligations. It considers inventory, excluding current assets, relative to current liabilities. A quick ratio of more than 1 is desirable, like the current ratio.
Cash Ratio: This is the most conservative ratio among the three, considering cash, cash equivalents and invested funds relative to current liabilities. It measures a company’s ability to meet existing debt obligations using the most liquid assets. Though a cash ratio of more than 1 may suggest sound financials, a higher number may indicate inefficiency in cash utilization.
A ratio greater than 1 is always desirable, but it may not always represent a company’s financial condition.
To pick the best of the lot, we have added asset utilization — a widely used measure of a company’s efficiency — as one of the screening criteria. Asset utilization is the ratio of total sales in the past 12 months to the last four-quarter average of total assets. Though this ratio varies across industries, companies with a ratio higher than that of their industry can be considered efficient.
We added our proprietary Growth Score to the screen to ensure these liquid and efficient stocks have solid growth potential.
Current Ratio, Quick Ratio, and Cash Ratio between 1 and 3: While liquidity ratios greater than 1 are desirable, significantly high ratios may indicate inefficiency.
Asset utilization is more significant than the industry average: A higher asset utilization than the industry average indicates a company’s efficiency.
Zacks Rank equal to #1 (Strong Buy): Only Strong Buy-rated stocks can get through. You can see the complete list of today’s Zacks #1 Rank stocks here.
Growth Score less than or equal to B: Back-tested results show that stocks with a Growth Score of A or B handily beat other stocks when combined with a Zacks Rank #1 or 2 (Buy).
These criteria have narrowed the universe of more than 7,700 stocks to only nine.
Here are four of the nine stocks that qualified the screen:
monday.com specializes in the development of software applications. Second-quarter 2026 revenues of $364.6 million increased 22% year over year, including an approximately 110 basis point favorable foreign exchange movement. AI adoption is emerging as a big growth opportunity. AI ARR doubled sequentially from the first quarter to the second quarter and accounted for 17% of net new ARR added during the quarter.
Customers generating more than $100,000 in ARR increased 37%, while those above $500,000 ARR jumped 68% year over year. Record net additions in both cohorts demonstrate that monday.com is successfully moving toward larger customers.
For the third quarter, monday.com expects revenues of $368-$370 million, implying 16%-17% year-over-year growth.
The Zacks Consensus Estimate for MNDY’s 2026 earnings is pegged at $5.38 per share, unchanged in the past seven days. The company has a Growth Score of B and an average trailing four-quarter earnings surprise of 23.56%.
Match Group is the parent company of brands like Tinder, Hinge, Match, Meetic, OkCupid, Plenty Of Fish and more, helping people make meaningful connections. Dating app Tinder is the company’s largest brand.
Second-quarter 2026 revenues of $853 million fell 1% year over year. Hinge remained a major growth contributor, with direct revenues rising 22% year over year to $204 million. Adjusted EBITDA surged 48% to $79 million. Global MAU increased 13%, supported particularly by expansion markets. The company’s potential growth driver is Tinder’s product-led turnaround. Management noted that updated recommendation algorithms have helped improve engagement, while Events could encourage new and lapsed users to reconsider Tinder. The company plans to expand Events from 10 cities currently to 26 cities by September and 75 cities by year-end.
For the third quarter, Match expects revenues of $885 million to $895 million, representing a year-over-year decline of 2% to 3%. The outlook includes a $10 million negative impact from Tinder user-experience tests and product changes, along with a $15 million negative impact from lower Azar revenues following its app redesign.
The Zacks Consensus Estimate for MTCH’s 2026 earnings stands at $4.13 per share, unchanged in the past seven days. The company has a Growth Score of B.
Progyny is a healthcare company specializing in women's health and family building solutions.
Second-quarter 2026 revenues were up 5.3% to $350.5 million. The top-line expansion was supported by a higher number of clients and covered lives but was partly offset by the impact of a large client who did not renew for 2025. This client contributed $17.2 million to revenues in the second quarter of 2025.
Fertility services remain Progyny’s core growth engine, with revenues jumping 7.6% year over year to $230.2 million. As of June 30, 2026, PGNY had 604 fertility and family-building clients. For 2026, Progyny expects revenues in the range of $1.36 billion to $1.385 billion, implying 5.5%–7.5% reported growth. The third quarter is expected to see slightly more pronounced seasonal softness related to member activity.
The Zacks Consensus Estimate for PGYNY’s 2026 earnings stands at $2.05 per share, unchanged in the past seven days. The company has a Growth Score of B and an average trailing four-quarter earnings surprise of 15.8%.
Workiva offers an AI-driven platform for accounting, finance, sustainability, risk, and audit teams. The company's second-quarter 2026 revenues jumped 19% to $255 million. The performance was driven by strong demand across the portfolio. Subscription & support revenues increased 19% year over year to $236 million.
Customers numbered 6,750 as of June 30, 2026, up 283 net customers from the prior-year period. Gross retention rate was 97%, while the net retention rate was 111%. Currently, 76% of subscription revenues come from multi-solution customers, up from 71% a year ago. Current remaining performance obligations were $789 million, up 18% year over year.
Workiva expects third-quarter revenues to be in the range of $260 million to $262 million, with operating margins between 17% and 17.5%. Full-year revenues are expected to be in the range of $1.04 billion to $1.044 billion.
The Zacks Consensus Estimate for 2026 earnings is pegged at $3.30 per share, unchanged over the past seven days. The company has a Growth Score of A and an average trailing four-quarter earnings surprise of 24.11%.
Bank of America Corp DE boosted its stake in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 75.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,190,996 shares of the company’s stock after acquiring an additional 511,609 shares during the quarter. Bank of America Corp DE owned about 1.52% of Progyny worth $20,223,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its stake in Progyny by 0.7% during the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after buying an additional 457 shares during the period. Teza Capital Management LLC increased its position in Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after acquiring an additional 516 shares during the last quarter. Aristides Capital LLC raised its stake in shares of Progyny by 4.6% in the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after acquiring an additional 528 shares during the period. Oxford Asset Management LLP raised its stake in shares of Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after acquiring an additional 531 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Progyny by 3.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,202 shares of the company’s stock worth $493,000 after acquiring an additional 637 shares during the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity In other news, Director Kevin K. Gordon sold 5,500 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total transaction of $137,445.00. Following the transaction, the director directly owned 9,318 shares in the company, valued at approximately $232,856.82. This trade represents a 37.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Allison Swartz sold 1,199 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $25.02, for a total transaction of $29,998.98. Following the completion of the transaction, the executive vice president directly owned 83,316 shares of the company’s stock, valued at $2,084,566.32. This trade represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 19,063 shares of company stock valued at $489,413. 9.90% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In Several brokerages recently commented on PGNY. KeyCorp upped their price target on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Barclays decreased their price objective on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 12th. Truist Financial boosted their target price on Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 13th. Finally, Leerink Partners set a $38.00 price target on Progyny in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.10. View Our Latest Stock Analysis on PGNY
Progyny Trading Up 1.5% Shares of PGNY stock opened at $25.71 on Wednesday. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 27.95, a P/E/G ratio of 1.91 and a beta of 1.01. The stock has a fifty day simple moving average of $29.15 and a two-hundred day simple moving average of $23.48.
Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $350.51 million for the quarter, compared to the consensus estimate of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Research analysts predict that Progyny, Inc. will post 1.19 EPS for the current fiscal year.
Progyny announced that its Board of Directors has authorized a share repurchase program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to repurchase up to 10.3% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Progyny Profile (Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Featured Articles Five stocks we like better than Progyny The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
3 Best Stocks to Buy That You’ve Probably Never Heard OfProgyny NASDAQ: PGNY CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management’s confidence in its outlook for the remainder of the year.
Speaking at the 46th Annual Canaccord Genuity Growth Conference, Anevski said Progyny has visibility into scheduled appointments for approximately the next six weeks and uses models to forecast utilization beyond that period. He said the company typically experiences seasonality in the second half of July and August, as some members delay fertility treatment because of summer travel, weddings and other personal plans.
Get Progyny alerts:
This year’s slowdown has been sharper than in recent years and more comparable to 2022, he said. However, Anevski said September appointment visibility indicates engagement and utilization returning to levels seen during the first half of the year.
“We wouldn’t put out guidance and expectations if we weren’t” comfortable with the outlook, Anevski said, adding that the early September activity is consistent with first-half trends.
Renewal commitments arrive earlier
Anevski said Progyny has received enough renewal commitments to “essentially de-risk” its renewal rates for next year earlier than it normally would in a sales cycle. About one-third of the company’s clients come up for renewal annually, generally under three-year contracts, he said.
Some employer clients renew directly, while others conduct requests for proposals or market checks. Anevski attributed the earlier decisions in part to broader medical-cost pressures facing employers. He said clients have not identified issues with Progyny’s reporting, member experience or performance.
Progyny also is seeing stronger early new-business commitments than it did at the same point last year, both in covered lives and expected contribution from those lives, according to Anevski. The company’s annual sales target is generally at least 1 million lives, and he said management expects to reach that goal based on current activity and the remaining pipeline.
While it is too early to quantify expansion activity at renewing clients, Anevski said Progyny historically sees roughly 20% to 30% of clients add something to their benefits. Potential additions include egg freezing, additional fertility treatment cycles, adoption and surrogacy coverage, global coverage, and ancillary postpartum maternity and menopause offerings.
He added that the company has received no indications that clients plan to reduce benefits.
More competitive replacement opportunities
The mix of early new-business commitments has included a higher proportion of “brownfield” opportunities than greenfield opportunities, Anevski said. He defined brownfield opportunities as employers that already offer fertility coverage through a health plan or another specialized provider.
According to Anevski, employers facing elevated medical-cost inflation are examining programs where they already spend money and seeking ways to improve efficiency. He said Progyny’s average cost per utilizer has risen relatively modestly over time compared with broader medical-cost inflation, which he characterized as running in the high-single-digit to low-double-digit range and expected to remain elevated next year.
Anevski also said the company’s client base has broadened substantially since its early years. Progyny began with five clients across two industries, including four technology clients, and has expanded into more than 45 industries, he said. The company generally sells into at least two-thirds of the industries it serves in a given year, although the specific industries vary.
He said adoption by major employers can encourage other companies within an industry to add the benefit as they compete for talent. Anevski cited the average age of women undergoing in vitro fertilization as 36, with much of Progyny’s utilization occurring among people ages 32 to 40. He said infertility affects one in five people in the U.S.
ROI, health-plan partnerships and cost management
Anevski distinguished Progyny’s offerings from traditional wellness programs, arguing that the company provides employers with hard-dollar savings calculations and detailed quarterly reporting. He said transparency around program costs, member outcomes and savings has supported Progyny’s 99% retention rate for 10 consecutive years.
He said health plans historically have not focused heavily on fertility-benefit management because their administrative-services business model does not necessarily produce more revenue from offering the coverage. In contrast, Progyny operates a proprietary provider network, offers care advocates and tracks outcomes, Anevski said.
The company has partnered with health plans, including Cigna, which began an expanded partnership effective in September of the prior year. Anevski said the current cycle is the first full sales season for that relationship and that Progyny is holding discussions with additional health plans regarding similar partnerships.
On medical-cost trends, Anevski said Progyny’s scale and network relationships have helped it contain provider rates, which he described as flat to down over time depending on the clinic. He also said the company’s improving outcomes contribute to savings for clients.
Expanded products and small-employer market
Progyny has approximately 7 million covered lives, with roughly 2.7 million having access to one or more expanded products, Anevski said. Those offerings include postpartum maternity and menopause programs, as well as Progyny Select.
Progyny Select is designed for employers with as few as 100 employees that typically purchase benefits on a fully insured, premium-based model. The product provides more predictable costs for smaller employers while placing them in a broader risk pool, Anevski said.
He said the company is working with channel partners, general agents and professional employer organizations to expand distribution of Progyny Select through broker networks. The offering increased Progyny’s estimated total addressable market by 50 million lives, to 155 million lives from 105 million previously, according to Anevski.
About Progyny (NASDAQ:PGNY)Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Progyny Right Now?Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
California State Teachers Retirement System lifted its position in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 30.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,753 shares of the company’s stock after buying an additional 23,273 shares during the period. California State Teachers Retirement System owned about 0.13% of Progyny worth $1,694,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of PGNY. Caitong International Asset Management Co. Ltd bought a new stake in Progyny in the 4th quarter valued at approximately $25,000. Hantz Financial Services Inc. grew its stake in shares of Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after acquiring an additional 742 shares in the last quarter. Quarry LP grew its stake in shares of Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after acquiring an additional 3,427 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Progyny during the 2nd quarter worth approximately $77,000. Finally, New Age Alpha Advisors LLC acquired a new stake in shares of Progyny in the fourth quarter valued at approximately $94,000. 94.93% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Progyny In related news, COO Melissa B. Cummings sold 9,578 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total transaction of $239,450.00. Following the transaction, the chief operating officer directly owned 73,371 shares in the company, valued at approximately $1,834,275. The trade was a 11.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $26.39, for a total transaction of $196,315.21. Following the sale, the director directly owned 19,772 shares in the company, valued at $521,783.08. This trade represents a 27.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 36,916 shares of company stock valued at $939,875 in the last 90 days. Company insiders own 9.90% of the company’s stock.
Wall Street Analysts Forecast Growth A number of analysts have recently commented on PGNY shares. Citigroup reissued an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Leerink Partners set a $38.00 price target on shares of Progyny in a research note on Wednesday, July 22nd. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Barclays cut their price target on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, Citizens Jmp increased their price objective on shares of Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.80.
View Our Latest Report on PGNY
Progyny Stock Down 4.3% Shares of Progyny stock opened at $25.42 on Thursday. The stock has a market cap of $1.95 billion, a P/E ratio of 27.63, a P/E/G ratio of 1.93 and a beta of 1.01. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $33.06. The business’s 50 day moving average is $29.15 and its 200-day moving average is $23.45.
Progyny announced that its Board of Directors has initiated a stock buyback plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.
Progyny Company Profile (Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Recommended Stories Five stocks we like better than Progyny GE Vernova’s AI Power Boom Faces a Profit Test Cardinal Health Earnings: Can Perfection Get Priced In Twice? Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia State Teachers Retirement System Grows Holdings in Innodata Inc. $INOD
NEXT HEADLINE »Hamilton Insurance Group, Ltd. $HG Shares Acquired by California State Teachers Retirement System
On August 11, 2026, Progyny Inc (PGNY) shares fell by 4.6%, bringing the current price to $26.55. The stock has seen significant volatility, with a 52-week high
Shares of fertility benefits management company Progyny (PGNY -5.36%) are down 6% on Friday as of 11 a.m. ET, after the company reported second-quarter earnings. Sales rose 5% (11% minus a large client's departure last year), and adjusted earnings per share jumped 15%, outpacing Wall Street's expectations. However, management guidance for Q3 sales to rise only 7% to 11%, along with a slight sequential earnings dip, prompted today's negative market reaction.
Today's Change
(
-5.36
%) $
-1.62
Current Price
$
28.59
I don't think this is bad guidance; it's probably just a bit conservative for a company heading into its busy season. Ultimately, it was a solid Q2 for Progyny as gross profit margins expanded 180 basis points, which is a big deal as the company morphs from a pure-growth stock to more of a profitable compounder (hopefully). Meanwhile, the average number of covered members rose by 7% to 7.2 million, and utilization rates continued to inch higher, suggesting that the company's suite of fertility and women's health solutions remains popular.
Image source: Getty Images.
While I'm hesitant to say just how wide Progyny's moat may be, management believes retention rates have been near 100% in 2026, and roughly 30% of clients have increased their buying. Now, Progyny is shifting its focus from companies with more than 1,000 employees to smaller firms with 100 or more employees through its Progyny Select offering. This is a pooled risk model that lets smaller employers participate in Progyny's offerings at a fixed price. This could make the offerings affordable for smaller companies that would previously have been scared off by large one-off costs incurred by their employees in the program.
This Progyny Select offering could provide the next chapter of growth for Progyny if all goes well, so I think the stock will be worth monitoring. Though the stock trades at 35 times free cash flow (after stock-based compensation), management has done a good job offsetting this dilution by lowering its share count by 8% annually over the last three years. Progyny is already a core holding for me, and I may add to my position in the stock again.
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET.
Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
3 Best Stocks to Buy That You’ve Probably Never Heard OfProgyny NASDAQ: PGNY reported record quarterly revenue, gross profit and adjusted EBITDA for the second quarter of 2026, while management said early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season.
Chief Executive Officer Pete Anevski said the quarter also featured gross-margin expansion and significant cash-flow generation. He said the company has used its financial performance to support investments in its platform while also repurchasing shares.
Get Progyny alerts:
Second-quarter revenue increased 5.3% from the prior-year period on a reported basis, Chief Financial Officer Mark Livingston said. Excluding revenue associated with a large former client that remained under a transition-of-care agreement during the second quarter of 2025, revenue rose 11%. That transition agreement ended June 30, 2025, meaning the second quarter was the last comparison period affected by the former client's contribution.
Margins expand as company continues investment program Gross margin expanded 180 basis points from a year earlier, matching the level of expansion reported in the first quarter, Livingston said. He attributed the improvement to continuing efficiencies in care management and service delivery, as well as lower stock-compensation expense.
Adjusted EBITDA margin also rose from the prior-year quarter, although at a slower pace than gross margin because platform investments were concentrated in operating expenses. On a trailing 12-month basis, adjusted EBITDA margin was 17.2%, Livingston said.
Capital expenditures totaled $6.2 million during the second quarter, consistent with first-quarter spending and about $1 million above the year-earlier period. Management expects its investment program to begin tapering in 2027, though Livingston said it was too early to provide detailed commentary beyond this year.
Operating cash flow exceeded $50 million for the fourth time in the past five quarters. Trailing 12-month operating cash flow was $201 million, and the company said it has generated more than $200 million in last-12-month operating cash flow for six consecutive quarters.
Working capital totaled about $273 million as of June 30. Cash, cash equivalents and marketable securities totaled $237 million. The company had no debt and no borrowings under its $200 million revolving credit facility. Days sales outstanding were more than seven days lower than a year earlier. Share repurchases reduce outstanding shares Progyny announced a new $200 million share-repurchase authorization in late May. During the portion of the second quarter in which the program was active, the company repurchased nearly 1.2 million shares for $31.5 million.
Including purchases after June 30, Progyny had bought 2 million shares under the latest authorization, with approximately $142.5 million remaining available. Across the current and prior $200 million programs, the company has repurchased 10.8 million shares since November, reducing shares outstanding by approximately 12.5%, Livingston said.
Anevski said the company expects its cash flow to provide flexibility for continued investment, potential acquisitions or tuck-in opportunities, further share repurchases and other uses of capital.
Early sales commitments support 2027 outlook Management said new-client commitments are pacing meaningfully ahead of the same point last year, with a higher-than-expected number of decisions occurring early in the selling season. Progyny maintained its target of adding 1 million or more new lives for 2027 launches.
Anevski said retention activity has also accelerated, led by the company’s largest clients. Based on current discussions and commitments, he said Progyny believes it has removed most of its retention risk earlier than usual. Roughly one-third of the company’s client book is up for renewal in a typical season.
The company said early wins span industries including energy, construction, manufacturing, aerospace, healthcare, labor, financial services and education, as well as clients ranging from 1,000 covered lives to large employers.
Management said employer interest is being shaped by rising costs in traditional medical and pharmacy coverage. Anevski said employers are increasingly focused on cost management, quality and member satisfaction, and that prospects moving through the sales cycle this year have been more weighted toward employers replacing an existing solution rather than first-time buyers of fertility benefits.
Progyny also cited progress with health-plan partnerships, public-sector clients and its fully insured offering, Progyny Select. The company expects Select’s initial phase to focus on building distribution relationships with general agents and brokers. Management does not expect the offering to make a meaningful contribution in 2027, instead describing it as a medium- and long-term growth initiative.
Guidance reflects summer seasonality For the third quarter, Progyny projected revenue of $335 million to $345 million, representing growth of 6.9% to 10.1%. The company expects adjusted EBITDA of $56 million to $59 million, net income of $24.5 million to $26.7 million, and adjusted earnings per share of $0.50 to $0.52 based on approximately 82 million fully diluted shares.
Livingston said the outlook incorporates a somewhat more pronounced seasonal slowdown during the middle of the summer. Management characterized the pattern as limited to the seasonally less-active summer period rather than evidence of a broader change in engagement trends. The company said appointment scheduling data provided some visibility into September and did not indicate the softer activity was extending beyond summer.
For full-year 2026, Progyny forecast revenue of $1.36 billion to $1.385 billion, representing reported growth of 5.5% to 7.5%. Excluding $48.5 million of transition-of-care revenue from the former client in the first half of 2025, the company projected growth of 9.7% to 11.7%.
The company expects full-year adjusted EBITDA of $233 million to $240 million, net income of $104.8 million to $109.9 million, and adjusted earnings per share of $2.04 to $2.10 based on approximately 83 million fully diluted shares.
About Progyny (NASDAQ:PGNY)Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Progyny Right Now?Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Progyny (PGNY - Free Report) reported $350.51 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.3%. EPS of $0.55 for the same period compares to $0.48 a year ago.
The reported revenue represents a surprise of +0.38% over the Zacks Consensus Estimate of $349.19 million. With the consensus EPS estimate being $0.51, the EPS surprise was +7.84%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Progyny performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Utilization - Female Only: 0.5% versus 0.5% estimated by two analysts on average.Revenue- Pharmacy benefit services revenue: $120.3 million versus $124.2 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +1.2% change.Revenue- Fertility benefit services revenue: $230.2 million versus the two-analyst average estimate of $225 million. The reported number represents a year-over-year change of +7.6%.View all Key Company Metrics for Progyny here>>>
Shares of Progyny have returned +2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Progyny (PGNY - Free Report) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.48 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +7.84%. A quarter ago, it was expected that this provider of fertility and family building benefits would post earnings of $0.44 per share when it actually produced earnings of $0.5, delivering a surprise of +13.64%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Progyny, which belongs to the Zacks Medical Services industry, posted revenues of $350.51 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.38%. This compares to year-ago revenues of $332.87 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Progyny shares have added about 22.2% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for Progyny?While Progyny has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Progyny was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.52 on $352.05 million in revenues for the coming quarter and $2.04 on $1.38 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Auna S.A. (AUNA - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 18.
This company is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -21.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Auna S.A.'s revenues are expected to be $350.52 million, up 13.4% from the year-ago quarter.
Wall Street expects a year-over-year increase in earnings on higher revenues when Progyny (PGNY - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis provider of fertility and family building benefits is expected to post quarterly earnings of $0.51 per share in its upcoming report, which represents a year-over-year change of +6.3%.
Revenues are expected to be $349.19 million, up 4.9% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 7.14% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Progyny?For Progyny, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.96%.
On the other hand, the stock currently carries a Zacks Rank of #1.
So, this combination makes it difficult to conclusively predict that Progyny will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Progyny would post earnings of $0.44 per share when it actually produced earnings of $0.50, delivering a surprise of +13.64%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Progyny doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsCharles River Laboratories (CRL - Free Report) , another stock in the Zacks Medical Services industry, is expected to report earnings per share of $2.72 for the quarter ended June 2026. This estimate points to a year-over-year change of -12.8%. Revenues for the quarter are expected to be $970.77 million, down 6% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Charles River has been revised 0.7% up to the current level. Nevertheless, the company now has an Earnings ESP of +1.43%, reflecting a higher Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #2 (Buy), suggests that Charles River will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026.
The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.
Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode.
An audio replay of the call will be available through Thursday, August 13, 2026 and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.
A live webcast and archive of the call will be available from the Events and Presentations section of the Company’s website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart [email protected]
Melissa B. Cummings, Chief Operating Officer of Progyny, Inc. (PGNY +0.22%), reported a sale of 3,437 shares of common stock on July 14, 2026. SEC Form 4 filing
Transaction summaryMetricValueShares sold3,437Transaction value~$109,056Post-transaction shares (directly held)69,934Post-transaction value$2.26 millionTransaction value based on SEC Form 4 weighted average sale price ($31.73); post-transaction value based on July 14, 2026, market close ($32.36).
Key questionsWhat were the primary drivers behind this equity disposition?
The transaction was structured to address both personal liquidity and tax obligations. Specifically, 2,244 shares were sold pursuant to a Rule 10b5-1 trading plan established on Dec. 19, 2025, while Progyny withheld 1,193 shares to cover tax liabilities stemming from the vesting of restricted stock units.How does this transaction affect the insider's total exposure to Progyny?
While direct holdings decreased by 5% in this filing, Cummings maintains a significant equity position of 69,934 shares. This remaining stake represents a 0.0893% ownership interest in the company, valued at $2.26 million based on the market close on the transaction date.What is the recent context of the stock's performance?
Progyny shares were priced at $32.36 at the close of July 14, 2026, the day the transaction occurred. At that time, the company had delivered a total return of 38% over the preceding 12 months. As of July 15, 2026, market close, the stock was priced at $32.34.Company OverviewMetricValueShare Price (as of market close 2026-07-15)$32.34Market Capitalization$2.5 billionRevenue (TTM)$1.3 billionNet Income (TTM)$67.7 millionCompany SnapshotProgyny operates as a specialized benefits management platform, providing comprehensive fertility and family-building solutions to employers. It features a distinctive benefits plan architecture, personalized member support services, and access to a curated network of top-tier fertility specialists, complemented by its Progyny Rx pharmaceutical offering.The company generates revenue through a subscription-based benefits management model where employers contract with Progyny to provide fertility and family-building benefits to their employees, supplemented by revenue from pharmaceutical services and ancillary offerings.Progyny primarily serves mid-to-large employers across the United States seeking to offer comprehensive fertility and family-building benefits as part of their employee benefits packages, addressing the growing demand for specialized reproductive health coverage.Progyny is a market-leading benefits management company with a $2.5 billion market capitalization, generating $1.3 billion in TTM revenue with $67.7 million in net income. The company has established a differentiated competitive position through its integrated platform combining benefits administration, personalized member services, and access to a selective network of fertility specialists, positioning it as a strategic partner for employers seeking to attract and retain talent through comprehensive family-building benefits.
What this transaction means for investorsCOO Cummings’ sales were pretty run-of-the-mill transactions. Some of it covered withholding taxes generated from restricted stock units, and the rest came from structured, pre-planned sales. Investors shouldn’t worry too much about these sales -- it wasn’t done in reaction to the stock’s price or its fundamentals.
As for Progyny’s stock, its share price has nearly doubled over the last few months after the company reported better-than-expected earnings and guidance in May. Despite losing one of its largest clients (suspected to be Amazon, though not confirmed), Progyny has rebounded nicely, delivering 1% sales growth in its most recent quarter, even though the customer accounted for 11 percentage points of a growth slowdown.
Meanwhile, Progyny’s margins have continued to improve, giving management the confidence to repurchase $200 million in shares, lowering its share count by 18% since 2024. Recently, another $200 million repurchase plan was put in place, which represents nearly 10% of its remaining shares. Progyny is a core holding for me, and I will continue adding to it over time. However, I’ll be watching customer concentration and a growing list of competitors very closely to see whether Progyny can gradually build a sustainable moat.
Key Takeaways The five stocks outperformed the S&P 500 over the past 12 weeks, four weeks and one week.VSXY surged 332.6% in a year, while its fiscal 2027 earnings estimate rose to $4.65 per share.PARR gained 131.7% in a year as its 2026 earnings estimate climbed 30.1% over the past 60 days. The U.S. stock market has remained resilient, with the S&P 500 gaining about 10% so far this year. Investors have been encouraged by steady economic data, as lower-than-expected jobless claims and stable retail sales suggest that consumer spending continues to hold up despite higher prices. The Federal Reserve reiterated that inflation remains above target but acknowledged the progress made, while stressing the central bank's commitment to making independent policy decisions.
Markets are also navigating a mix of external risks. Ongoing tensions in the Middle East and proposed U.S. tariffs on selected Brazilian imports have added uncertainty, even as Iran's release of an American prisoner has raised hopes for a gradual easing of geopolitical strains. Meanwhile, low U.S. crude inventories could keep energy prices elevated and weigh on some sectors.
Even with these headwinds, the market's ability to advance reflects underlying strength. In this environment, focusing on stocks with strong relative price strength can be a sensible strategy, as companies consistently outperforming the broader market are often better positioned to weather uncertainty and benefit when investor confidence remains intact.
At this stage, investors would be wise to consider companies such as J.B. Hunt Transport Services (JBHT - Free Report) , Progyny (PGNY - Free Report) , Bassett Furniture Industries (BSET - Free Report) , Victoria's Secret & Co. (VSXY - Free Report) and Par Pacific Holdings (PARR - Free Report) .
Relative Price Strength Strategy
Whether a stock has the potential to offer considerable returns is determined primarily by its earnings and valuation ratios. Simultaneously, it is essential to check whether its price performance exceeds its peers or the industry average.
Upon such comparison, if we find that a stock is unable to match up to wider sectoral growth despite having impressive earnings momentum or valuation multiples, it may be better to avoid it.
However, those outperforming their respective industries or benchmarks should be included in your portfolio since they have a higher chance of securing significant returns. Picking a stock that outperforms its peers ensures a winning option on your hands.
Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals, indicate room for growth and the best way to go about this strategy.
Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.
Screening Parameters
Relative % Price change – 12 weeks greater than 0
Relative % Price change – 4 weeks greater than 0
Relative % Price change – 1 week greater than 0
(We have considered those stocks that have been outperforming the S&P 500 over the last 12 weeks, four weeks and one week.)
% Change (Q1) Est. over 4 Weeks greater than 0: Positive current-quarter estimate revisions over the last four weeks.
Zacks Rank equal to 1: Only Zacks Rank #1 (Strong Buy) stocks — that have returned more than 26% annually over the last 26 years and surpassed the S&P 500 in 23 of the last 26 years — can get through. You can see the complete list of today’s Zacks #1 Rank stocks here.
Current Price greater than or equal to $5 and Average 20-day Volume greater than or equal to 50,000: A minimum price of $5 is a good standard to screen low-priced stocks, while a high trading volume would imply adequate liquidity.
VGM Score less than or equal to B :Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), offer the best upside potential.
Here are five of the 12 stocks that made it through the screen:
J.B. Hunt Transport Services: It is a provider of a wide range of transportation, brokerage, and delivery services to a diverse group of customers through the United States, Canada and Mexico. The Zacks Consensus Estimate for J.B. Hunt’s 2026 earnings indicates 20.1% growth. JBHT has a VGM Score of B.
J.B. Hunt beat the Zacks Consensus Estimate for earnings in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 9.8%, on average. JBHT shares have gained 100.4% in a year.
Progyny: Progyny provides fertility and family-building benefits for employers. Its platform combines treatment coverage, pharmacy support, a selected provider network and patient guidance, helping members access care while clients manage costs and strengthen employee satisfaction. The Zacks Consensus Estimate for 2026 earnings of Progyny indicates 7.9% growth. PGNY has a VGM Score of A.
Over the past 60 days, the Zacks Consensus Estimate for Progyny’s 2026 earnings has moved up 3.6%. The company has a market capitalization of $2.5 billion. PGNY shares have gone up 44.8% in a year.
Bassett Furniture Industries: Bassett Furniture designs, manufactures and sells home furnishings through a network of company-owned and licensed stores offering free in-home design services. The company’s expected EPS growth rate for three to five years is currently 16%, which compares favorably with the industry's growth rate of 13%. BSET has a VGM Score of B.
Over the past 60 days, the Zacks Consensus Estimate for Bassett Furniture’s fiscal 2026 earnings has moved up 7.2%. The Zacks Consensus Estimate for fiscal 2026 earnings indicates 18.7% growth. BSET shares have gained 17.2% in a year.
Victoria's Secret & Co.: It is a specialty retailer of women's intimates, sleepwear, apparel, sportswear and swimwear, and prestige fragrances and body care sold under the Victoria's Secret, PINK and Adore Me brands. Victoria's Secret’s expected EPS growth rate for three to five years is currently 27.4%, which compares favorably with the industry's growth rate of 15.5%. The company has a VGM Score of A.
VSXY has a trailing four-quarter earnings surprise of roughly 55.1%, on average. Over the past 60 days, the Zacks Consensus Estimate for Victoria’s Secret’s fiscal 2027 earnings has moved up from $3.49 per share to $4.65. VSXY’s shares have gone up 332.6% in a year.
Par Pacific Holdings: Par Pacific is an integrated energy company that produces conventional and renewable fuels across the western United States. Its operations combine refining, logistics and fuel retailing, supported by a broad transportation and storage network. The Zacks Consensus Estimate for 2026 earnings of Par Pacific indicates 136.1% growth. PARR has a VGM Score of A.
Over the past 60 days, the Zacks Consensus Estimate for Par Pacific’s 2026 earnings has moved up 30.1%. The company has a market capitalization of $3.7 billion. PARR shares have gone up 131.7% in a year.
Have you been paying attention to shares of Progyny (PGNY - Free Report) ? Shares have been on the move with the stock up 18.8% over the past month. The stock hit a new 52-week high of $32 in the previous session. Progyny has gained 24.5% since the start of the year compared to the 0.3% move for the Zacks Medical sector and the 0.2% return for the Zacks Medical Services industry.
What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on May 7, 2026, Progyny reported EPS of $0.5 versus consensus estimate of $0.44.
For the current fiscal year, Progyny is expected to post earnings of $2.04 per share on $1.38 in revenues. This represents a 7.94% change in EPS on a 7.01% change in revenues. For the next fiscal year, the company is expected to earn $2.31 per share on $1.49 in revenues. This represents a year-over-year change of 13.24% and 8.26%, respectively.
Valuation MetricsWhile Progyny has moved to its 52-week high in the recent past, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Progyny has a Value Score of C. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 15.7X current fiscal year EPS estimates, which is not in-line with the peer industry average of 15.7X. On a trailing cash flow basis, the stock currently trades at 43.4X versus its peer group's average of 10.2X. Additionally, the stock has a PEG ratio of 1.48. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Progyny currently has a Zacks Rank of #1 (Strong Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Progyny meets the list of requirements. Thus, it seems as though Progyny shares could have potential in the weeks and months to come.
How Does PGNY Stack Up to the Competition?Shares of PGNY have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is PACS Group, Inc. (PACS - Free Report) . PACS has a Zacks Rank of #2 (Buy) and a Value Score of B, a Growth Score of A, and a Momentum Score of B.
Earnings were strong last quarter. PACS Group, Inc. beat our consensus estimate by 19.05%, and for the current fiscal year, PACS is expected to post earnings of $2.23 per share on revenue of $5.71 billion.
Shares of PACS Group, Inc. have gained 19.4% over the past month, and currently trade at a forward P/E of 19.4X and a P/CF of 27.07X.
The Medical Services industry is in the top 41% of all the industries we have in our universe, so it looks like there are some nice tailwinds for PGNY and PACS, even beyond their own solid fundamental situation.
Progyny (PGNY - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.
Analysts' growing optimism on the earnings prospects of this provider of fertility and family building benefits is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Progyny, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate RevisionsThe company is expected to earn $0.51 per share for the current quarter, which represents a year-over-year change of +6.3%.
The Zacks Consensus Estimate for Progyny has increased 7.14% over the last 30 days, as one estimate has gone higher compared to no negative revisions.
Current-Year Estimate RevisionsFor the full year, the company is expected to earn $2.04 per share, representing a year-over-year change of +7.9%.
The revisions trend for the current year also appears quite promising for Progyny, with one estimate moving higher over the past month compared to no negative revisions. The consensus estimate has also received a boost over this time frame, increasing 11.22%.
Favorable Zacks RankThe promising estimate revisions have helped Progyny earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom LineInvestors have been betting on Progyny because of its solid estimate revisions, as evident from the stock's 18.8% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.
Investors might want to bet on Progyny (PGNY - Free Report) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for Progyny basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For Progyny, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for ProgynyFor the fiscal year ending December 2026, this provider of fertility and family building benefits is expected to earn $2.04 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Progyny. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.3%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Progyny to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Progyny (PGNY - Free Report) , which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Progyny currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if PGNY is a promising momentum pick, let's examine some Momentum Style elements to see if this provider of fertility and family building benefits holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For PGNY, shares are up 6% over the past week while the Zacks Medical Services industry is up 1.95% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 18.81% compares favorably with the industry's 3.18% performance as well.
Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of Progyny have risen 76.88%, and are up 29.35% in the last year. On the other hand, the S&P 500 has only moved 10.61% and 21.48%, respectively.
Investors should also take note of PGNY's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now PGNY is averaging 1,299,750 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with PGNY.
Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. This revision helped boost PGNY's consensus estimate, increasing from $1.97 to $2.04 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that PGNY is a #1 (Strong Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Progyny on your short list.
Mark S. Livingston, Chief Financial Officer of Progyny (PGNY +0.45%), reported the sale of 8,275 shares of common stock in an open-market transaction on May 20, 2026, as disclosed in an SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)8,275Transaction value$211,000Post-transaction shares (direct)79,063Post-transaction value (direct ownership)$2.03 millionTransaction value based on SEC Form 4 reported price ($25.50); post-transaction value based on May 20, 2026 trade-date close price.
Key questionsHow meaningful was this sale as a proportion of Livingston's direct holdings?
This transaction represented 9.47% of Livingston's direct position, a moderate reduction consistent with the cadence of his prior open-market sales.Did the sale affect indirect or derivative holdings?
No indirect or derivative holdings were reported; the activity was limited to directly held common shares, leaving Livingston with 79,063 shares post-transaction.What does the transaction reveal about selling cadence and capacity?
Recent sales have corresponded to a decline in total available shares, with remaining direct holdings now at 43.2% of the level held in July 2023, indicating that trade size reductions are a function of reduced capacity rather than a change in selling intent.Company overviewMetricValueRevenue (TTM)$1.29 billionNet income (TTM)$67.69 millionEmployees675Price (as of market close 5/20/26)$25.64* 1-year performance metrics are calculated using May 20th, 2026 as the reference date.
Company snapshotProgyny offers fertility and family building benefits solutions, including differentiated plan designs, member support services, a selective network of fertility specialists, and an integrated pharmacy benefits platform.It operates a benefits management model, generating revenue through employer-sponsored health benefit programs and pharmacy solutions.The company serves employers across the United States seeking fertility and family-building benefits for their employees.Progyny is a leading provider of fertility and family building benefits, leveraging a data-driven platform and selective provider network to deliver tailored solutions for employers. The company’s integrated approach combines plan design, member support, and pharmacy management, positioning it as a differentiated player in the healthcare benefits space.
What this transaction means for investorsThe May 20 sale of Progyny stock by CFO Mark Livingston came at a time when shares were on the upswing. His disposition at $25.50 per share was close to the 52-week high of $28.75 reached in January. He subsequently sold additional shares in June.
Even so, Livingston’s sales are not a red flag for investors. They were non-discretionary transactions performed as part of a pre-arranged Rule 10b5-1 trading plan, adopted back in August of 2025. Such plans are often implemented by insiders to avoid accusations of trading based on insider information.
Progyny lost a major customer, but its shares rose in the second quarter after the company delivered strong full-year guidance for 2026. It projects revenue will increase between 6% to 9% year over year.
Excluding the sales delivered by the one large client from 2025 totals, the year-over-year revenue growth would be a whopping 10% to 13%. This suggests Progyny is seeing increased income from other customers.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Progyny. The Motley Fool has a disclosure policy.
On June 12, 2026, Progyny Inc PGNY shares rose 3.8% to $26.63. The stock has traded within a 52-week range of $16.10 to $28.75, indicating considerable volatility over the past year. This recent price movement reflects a growing interest in the stock.
GF Value™ verdict: Current price is $26.63, which is 5.0% below the GF Value™ of $28.04.GF Score™: 92/100, indicating a strong overall rating.Most notable signal: Financial strength, rated at 8/10. Is PGNY Overvalued or Undervalued? Progyny Inc's current price of $26.63 is slightly below its GF Value™ of $28.04, suggesting that the stock is undervalued by approximately 5.0%. This margin of safety indicates a potential opportunity for investors looking for stocks that are trading below their intrinsic value. The GF Valuation label categorizes the stock as fairly valued, which aligns with its current trading position just below the calculated fair value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the stock presents an opportunity, it is important to consider that market conditions can change swiftly. Investors should remain cautious, especially in light of the overall market environment and Progyny's performance over the last three years, which has seen a decline of 12.3%.
How Does PGNY's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 34.6x 58.0x Forward P/E 21.2x N/A Progyny's current P/E (TTM) of 34.6x is significantly below its 5-year median P/E of 58.0x, indicating that the stock is trading at a lower valuation compared to its historical averages. The forward P/E of 21.2x further emphasizes this trend, suggesting potential for increased earnings in the future. This P/E analysis agrees with the GF Value™ verdict, reinforcing the notion that the stock is undervalued relative to its historical performance.
What Does PGNY's GF Score™ Tell Us? Metric Rating GF Score™ 92 Financial Strength 8/10 Profitability 8/10 Growth 10/10 Valuation 10/10 Momentum 5/10 Progyny's GF Score™ of 92/100 illustrates a strong overall performance in financial health, profitability, growth, and valuation, with particularly high ratings in growth (10/10) and valuation (10/10). The weakest area appears to be momentum, rated at 5/10, suggesting that while the stock has potential, its recent performance may not exhibit the same strength as its financial fundamentals. This combination suggests that while the company is fundamentally strong, it may face challenges in maintaining upward momentum in the short term.
What Are Insiders Doing with PGNY Stock? In the last three months, insiders have sold approximately $1.0 million worth of shares with no reported buying activity. This selling pattern may raise some concerns among potential investors, as it could indicate a lack of confidence from those closest to the company. However, insider selling can also occur for various reasons unrelated to the company's performance or outlook.
Overall, the absence of insider buying in conjunction with recent selling activity suggests caution, as it may reflect a sentiment among insiders regarding the stock's current valuation or future prospects.
What This Means for Investors Based on the current assessment, Progyny Inc PGNY is considered undervalued with a GF Value™ of $28.04 compared to its current price of $26.63. While the stock shows potential based on its strong financial fundamentals, investors should remain aware of the insider selling activity and the recent volatility in its performance.
For the complete analysis, visit the Progyny Inc PGNY stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is PGNY's GF Score™?
PGNY has a GF Score™ of 92/100, indicating a strong overall assessment based on key aspects of financial health, profitability, growth, valuation, and momentum.
Is PGNY overvalued or undervalued?
PGNY is currently undervalued, with a GF Value™ of $28.04 compared to its current price of $26.63, suggesting a 5.0% margin of safety.
What is PGNY's P/E ratio?
PGNY's P/E (TTM) is 34.6x, which is significantly below its 5-year median P/E of 58.0x, indicating it is trading at a lower valuation compared to its historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully insured, comprehensive supplemental fertility and family building plan. Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model.
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026.
Progyny, Inc. (NASDAQ: PGNY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target
Investors with an interest in Medical Services stocks have likely encountered both Progyny (PGNY) and Alignment Healthcare (ALHC). But which of these two stocks is more attractive to value investors?
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 (“the first quarter of 2026”), as compared to the three-month period ended March 31, 2025 (“the first quarter of 2025” or “the prior year period”). “We're pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals,” said Pete Anevski, Chief Executive Officer of Progyny.
Progyny (PGNY) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.48 per share a year ago.
Progyny NASDAQ: PGNY reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time.
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, Progyny (PGNY) stock deserves a close look.
On May 21, 2026, Progyny Inc (PGNY) shares fell 3.8%, closing at $24.69. This decline comes amidst a 52-week range where the stock has seen a high of $28.75 and
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances.
Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience
